Breaking News
Get 50% Off 0
🏄 Grow your portfolio even on vacation with InvestingPro | Summer Sale 50% OFF
CLAIM SALE
Close

Collegium Pharmaceutical Inc (COLL)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Collegium Pharmaceutical's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
36.14 +1.21    +3.46%
11/08 - Closed. Currency in USD
Pre Market
36.65
+0.51
+1.41%
12:00:08 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 641,491
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 34.93 - 36.63
Collegium Pharmaceutical 36.14 +1.21 +3.46%

Collegium Pharmaceutical Inc Company Profile

 
Get an in-depth profile of Collegium Pharmaceutical Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

357

Equity Type

ORD

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company’s portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Contact Information

Address 100 Technology Center Drive Suite 300
Stoughton, 02072
United States
Phone 781 713 3699
Fax -

Top Executives

Name Age Since Title
John A. Fallon 77 2016 Independent Director
John Gordon Freund 71 2014 Independent Director
Garen G. Bohlin 78 2015 Independent Director
Gino Santini 68 2012 Independent Chairman
Vikram Karnani 50 2024 CEO, President, Executive VP & Director
Carlos V. Paya 66 2025 Independent Director
William T. Zempsky - - Scientific Advisor
Charles E. Argoff - - Scientific Advisor
Robert H. Dworkin - - Scientific Advisor
Bill McCarberg - - Scientific Advisor
Lynn R. Webster - - Scientific Advisor
Nathaniel P. Katz - - Scientific Advisor
Richard L. Rauck - - Scientific Advisor
Joseph V. Pergolizzi 55 - Scientific Advisor
Srinivas Nalamachu - - Scientific Advisor
Cynthia G. McCormick - - Scientific Advisor
Rita J. Balice-Gordon 64 2020 Independent Director
Nancy S. Lurker 68 2025 Independent Director
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

COLL Comments

Write your thoughts about Collegium Pharmaceutical Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Apple
Continue with Google
or
Sign up with Email